Nivolumab and pembrolizumab, two humanized monoclonal antibodies targeting PD-1, were granted accelerated approval by the FDA for advanced HCC treatment as a second-line treatment following phase II clinical trials 7, 8. Here, PDCD1 is linked to hepatocellular carcinoma.